Last Day
Biotechnology
Latest Valuation
- Trailing PE:
- Forward PE:
- Price Sales TTM:
- Price Book MRQ:
- Enterprise Value:
- Enterprise Value Revenue:
- Enterprise Value Ebitda:
- Beta:
Key Highlights
- Shares Outstanding:
- Market Capitalization:
- Market Capitalization Mln:
- EBITDA:
- PE Ratio:
- PEG Ratio:
- Wall Street Target Price:
- Book Value:
- Dividend Share:
- Dividend Yield:
- Earnings Share:
- EPS Estimate Current Year:
- EPS Estimate Next Year:
- EPS Estimate Next Quarter:
- EPS Estimate Current Quarter:
- Most Recent Quarter:
- Profit Margin:
- Operating Margin TTM:
- Return On Assets TTM:
- Return On Equity TTM:
- Revenue TTM:
- Revenue Per Share TTM:
- Quarterly Revenue Growth YOY:
- Gross Profit TTM:
- Diluted Eps TTM:
- Quarterly Earnings Growth YOY:
Basic Information
- Type:
- Name:
- Exchange:
- Currency Code:
- Currency Name:
- Currency Symbol:
- Country Name:
- Fiscal Year End:
- IPO Date:
- International Domestic:
- Sector:
- Industry:
- Address:
- Country:
- Listings:
- Web URL:
- Full Time Employees:
- Updated At:
- Gic Sector:
- Gic Group:
- Gic Industry:
- Gic SubIndustry:
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York. Address: 230 Park Avenue, New York, NY, United States, 10169